Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma
Multiple MyelomaCompassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma...
Relapsed or Refractory Multiple MyelomaThe purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients...
Relapsed or Refractory Multiple MyelomaThe purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS)...
Multiple MyelomaThe purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaThis is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
Multiple MyelomaThis is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.
Expanded Access Treatment Protocol CA204-143
Multiple MyelomaThe objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor...
Non-Hodgkin's LymphomaHodgkin's Disease1 moreThe purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric...
Multiple MyelomaThe purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization. Such access may be considered for participants with serious/life-threatening diseases or conditions, where there exists no alternative treatments or where alternative treatments have been exhausted.
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of...
Multiple Myeloma in RelapseMultiple MyelomaParticipant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657